Newsletter

249420 - Ildong Pharm

249420 Summary
Biopharma
Stock Price & Overview
₩15,030 -70 (-0.46%) Close · Sep 4, 2026 KST
KOSPI | ₩KRW | Close: ₩15,030  ≈ US$11  ·  Market cap ₩0.5tn (≈ $340m)

249420 Quarterly Results

Quarter ₩bnRevenueYoYOperating incomeMarginYoYNet incomeEPS
2026 Q2147.9+6.8%2.01.3%+232.1%5.1₩161
2026 Q1142.0+4.4%9.26.5%+120.0%7.4₩233
2025 Q4147.0-5.6%7.95.4%-5.7%5.6₩177
2025 Q3145.5-6.7%6.84.6%+87.6%21.5₩679
2025 Q2138.5-9.0%0.60.4%-41.4%-3.9₩-123
2025 Q1136.0-10.0%4.23.1%+4,274.8%0.5₩16
2024 Q4155.7—8.45.4%—2.9₩90
2024 Q3155.9—3.62.3%—-9.2₩-290
Three-month figures from DART consolidated statements. Q4 is the annual figure less the nine-month cumulative. EPS is net income over today's share count, so buybacks and issuance move earlier quarters. YoY compares with the same quarter a year earlier and is blank when that quarter was a loss.

249420 Annual Results

Full statements »
Fiscal year ₩bnRevenueYoYOperating incomeMarginYoYNet incomeEPS
FY2025566.9-7.8%19.53.4%+48.5%23.7₩749
FY2024614.9+2.4%13.12.1%—-12.4₩-392
FY2023600.8-5.8%-53.9-9.0%—-81.0₩-2,559
FY2022637.7+13.9%-73.5-11.5%—-142.2₩-4,494
FY2021560.1-0.3%-55.5-9.9%-937.3%-101.0₩-3,191
FY2020561.8+8.6%6.61.2%—-13.0₩-412

249420 Next Report

The latest quarter on file is 2026 Q2. The next one, the Q3 2026 report covering the period to Sep 30, 2026, is due on DART by Nov 14, 2026 — Korean issuers must file quarterly and half-year reports within 45 days of period end and the annual report within 90 days.

Large issuers usually publish preliminary consolidated figures (잠정실적, a fair-disclosure filing with revenue and operating profit only) in the first weeks after the period ends, ahead of the full report. kstock does not know a company's chosen release date; when the preliminary filing arrives it appears under Filings and on this page.

249420 Earnings Filings

All filings »
DART

Half-Year Report

Periodic08/14/26title translated
DART

Preliminary Consolidated Results (Fair Disclosure)

Earnings07/30/26title translated
DART

Quarterly Report

Periodic05/15/26title translated
DART

Preliminary Consolidated Results (Fair Disclosure)

Earnings05/13/26title translated

How Korean earnings differ from US earnings

  • No quarterly guidance culture. Most KRX companies give no EPS or revenue guidance; the preliminary filing is the first number the market sees, and there is no consensus beat/miss ritual built around it.
  • Preliminary first, then the report. The 잠정실적 filing carries revenue and operating profit; net income and the balance sheet come with the full report weeks later.
  • Consolidated is the headline. Korean companies report consolidated (K-IFRS) and separate (parent-only) figures; kstock uses consolidated unless the page says otherwise.
  • Fiscal years end in December for almost every listed company, so Q4 is derived: the annual figure less the nine-month cumulative.

Similar to 249420

SymbolLast Price
085660Chabiotech Co., Ltd.₩8,090
+2.1%
476060Onconic Therapeutics, Inc.₩16,440
-3.9%
041960Komipharm International Co., Ltd.₩9,710
+3.5%
317450Myungin Pharm₩44,650
+0.0%
001060JW Pharmaceutical₩27,500
+1.3%
456160G2GBIO, Inc.₩37,950
+5.7%
019170Shinpoong Pharmaceutical Co., Ltd.₩10,010
-0.9%
358570GI Innovation, Inc.₩8,090
+6.2%
086900Medy-Tox, Inc.₩69,600
+0.4%
397030April Bio Co., Ltd.₩17,800
+6.1%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.